Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
Fuente:
FierceBiotech
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.